Zhao Yichao, Gao Lingchen, Jiang Chenglin, Chen Jianqing, Qin Zihan, Zhong Fangyuan, Yan Yang, Tong Renyang, Zhou Meng, Yuan Ancai, Pu Jun
State Key Laboratory for Oncogenes and Related GenesDivision of CardiologyRenji HospitalSchool of MedicineShanghai Jiao Tong UniversityShanghai Cancer InstituteShanghaiChina.
Graduate School of Bengbu Medical CollegeBengbuAnhuiChina.
Hepatology. 2022 Apr;75(4):939-954. doi: 10.1002/hep.32165. Epub 2022 Feb 16.
NASH, which is a common clinical condition predisposing to advanced liver diseases, has become a worldwide epidemic. A large and growing unmet therapeutic need for this condition reflects incomplete understanding of its pathogenesis. In the current study, we identified a transcription factor, zinc fingers and homeoboxes 2 (ZHX2), in hepatocytes as a protective factor against steatohepatitis.
We found that hepatic ZHX2 was significantly suppressed in NASH models and steatotic hepatic cells. Hepatocyte-specific ablation of ZHX2 exacerbated NASH-related phenotypes in mice, including lipid accumulation, enhanced inflammation, and hepatic fibrosis. Conversely, hepatocyte-specific overexpression of ZHX2 significantly alleviated the progression of NASH in an experimental setting. Integrated analysis of transcriptomic profiling and chromatin immunoprecipitation sequencing data demonstrated that the phosphatase and tensin homolog (PTEN) was a target gene of ZHX2 in hepatocyte. ZHX2 bound to the promoter of PTEN gene and subsequently promoted the transcription of PTEN, which mediated the beneficial role of ZHX2 against NASH.
The current findings demonstrate a protective role of ZHX2 against NASH progression by transcriptionally activating PTEN. These findings shed light on the therapeutic potential of targeting ZHX2 for treating NASH and related metabolic disorders.
非酒精性脂肪性肝炎(NASH)是一种易导致晚期肝病的常见临床病症,已成为全球性的流行病。对这种病症大量且不断增加的未满足治疗需求反映出对其发病机制的理解尚不完整。在本研究中,我们在肝细胞中鉴定出一种转录因子——锌指和同源盒蛋白2(ZHX2),它是抗脂肪性肝炎的保护因子。
我们发现,在NASH模型和脂肪变性肝细胞中,肝脏中的ZHX2显著受到抑制。肝细胞特异性敲除ZHX2会加剧小鼠中与NASH相关的表型,包括脂质蓄积、炎症增强和肝纤维化。相反,在实验环境中,肝细胞特异性过表达ZHX2可显著减轻NASH的进展。转录组分析和染色质免疫沉淀测序数据的综合分析表明,磷酸酶和张力蛋白同源物(PTEN)是肝细胞中ZHX2的靶基因。ZHX2与PTEN基因的启动子结合,随后促进PTEN的转录,这介导了ZHX2对NASH的有益作用。
当前研究结果表明ZHX2通过转录激活PTEN对NASH进展具有保护作用。这些发现揭示了靶向ZHX2治疗NASH及相关代谢紊乱的治疗潜力。